Kevin F Mclaughlin is Director of Decibel Therapeutics, Inc.. Currently has a direct ownership of 0 shares of DBTX, which is worth approximately $0. The most recent transaction as insider was on Sep 25, 2023, when has been sold 5,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

KEVIN F MCLAUGHLIN Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 25 2023
SELL
Sale (or disposition) back to the issuer
-
5,000 Reduced 100.0%
0 Common Stock
Jun 13 2023
BUY
Grant, award, or other acquisition
-
5,000 Added 50.0%
5,000 Common Stock

Also insider at

XLRN
ACCELERON PHARMA INC Healthcare
VCEL
Vericel Corp Healthcare
ADGI
Adagio Therapeutics, Inc. Healthcare
KFM

Kevin F Mclaughlin

Director
Cambridge, MA

Track Institutional and Insider Activities on DBTX

Follow Decibel Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DBTX shares.

Notify only if

Insider Trading

Get notified when an Decibel Therapeutics, Inc. insider buys or sells DBTX shares.

Notify only if

News

Receive news related to Decibel Therapeutics, Inc.

Track Activities on DBTX